3Carri6n JA, Navasa M, Bosch J, et al. Transient elastog- raphy for diagnosis of advanced fibrosis and portal hyper- tension in patients with hepatitis C recurrence after liver transplantation[J]. Liver Transpl,2006,12( 12): 1791-1798. 被引量：1
4Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in pa- tients with HCV-related cirrhosis[J]. Hepatology,2007,45(5): 1290-1297. 被引量：1
9Singal AK, Salameh H, Kamath PS. Prevalence and in- hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States[J]. Aliment Pharmacol Ther,2014,40(1): 105-112. 被引量：1
10Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrho- sis: an update[J]. Hepatology,2009,49(6):2087-2107. 被引量：1
6Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
9Dzeletovic I, Baron TH. History of portal hypertension and endoscopic treatment of esophageal varices[J]. Gastrointest Endosc, 2012,75(6) : 1244-1249. 被引量：1
10Bosch J, Abraldes JG, Berzigotti A,et al. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol, 2009,6 (10) :573-582. 被引量：1
1Bayraktar Y, Balkanci F, Uzunalimoglu B, et al. Is portal hypertension due to liver cirrhosis a major factor in the development of portal hypertensive gastropathy? [J]. Am J Gastroenterol, 1996,91 (3) : 554-558. 被引量：1
2Carri6n JA, Navasa M, Bosch J,et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation[J]. Liver Transpl,2006,12(12) :1791-1798. 被引量：1
3Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV related cirrhosis [ J ]. Hepatology, 2007, 45 (5): 1290 1297. 被引量：1
4Serst T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology,2010,52(3) : 1017-1022. 被引量：1
5Reiberger T, Ulbrieh G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non response to propranolol [J]. Gut, 2013, 6201), 1634-1641. 被引量：1
6Hobolth L, Moiler S, Grnbmk H, et al. Carvedilol or propranolol in portal hypertension? A randomized comparison[J]. Scand J Gastroenterol, 2012, 47(4) : 467-474. 被引量：1
7D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach[J]. Semin Liver Dis, 1999, 19(4): 475-505. 被引量：1
8Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults [J ]. Cochrane Database Syst Rev,2012,15(8): CD004544. 被引量：1
9Bai M, Qi X, Yang M, et al. Combined therapies versus monothera-pies for the first variceal bleeding in patients with high-risk varices: a recta-analysis of randomized controlled trials[J]. J Gastroenterol Hepatol, 2014, 29(3): 442- 452. 被引量：1
10Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients [J]. Gut, 2005, 64(11): 1680-1704. 被引量：1
